Tagged Articles

AbbVie Inc. 34 articles

Judge orders new trial in first testosterone side effects bellwether

U.S. District Judge Matthew Kennelly ordered a new trial in the first bellwether against AbbVie Inc., in a multidistrict litigation accusing testosterone replacement therapy manufacturers of failing to warn of cardiovascular risks, finding that the jury must have misunderstood the issue of causation. Plaintiff Jesse Mitchell claimed AbbVie’s testosterone treatment AndroGel was not adequately tested to better understand its cardiovascular risks. Despite this, the company aggressively marketed the drug for the off-label treatment of a made-up condition they called Low T. The jury awarded Mitchell $150 million in punitive damages, finding the company misrepresented its testosterone therapy. But the jury ... Read More

AndroGel asks for new trial after $140M verdict

AbbVie Inc., asked an Illinois federal judge for a new trial in a case involving claims the company failed to warn that its testosterone replacement therapy AndroGel could cause cardiovascular risks. AbbVie was slapped with $140 million in damages after a jury found the company liable for plaintiff Jeffrey Konrad’s 2010 heart attack. AbbVie argued that the plaintiff’s claims that the company was negligent and misrepresentative required Konrad to prove causation and unreasonable dangerousness. “By finding for AbbVie on one claim and for the plaintiff on the other, the jury necessarily reached inconsistent conclusions on one or both of those ... Read More

Yale doc says AndroGel caused blood clots in man’s lungs

A Yale School of Medicine physician, testifying on behalf of a man who blamed AbbVie Inc.’s AndroGel for causing blood clots in his lungs, said that the hormone replacement therapy does, in fact, increase the risk of dangerous blood clots in men who use the treatment. Yale hematologist Dr. Henry Rinder told an Illinois federal jury earlier this week that he believes that plaintiff Robert Nolte would not have suffered from a pulmonary embolism – or blood clots in his lungs – and several related injuries had he not been taking AndroGel. Nolte is suing AbbVie for failing to warn ... Read More

Lilly pulls Axiron from Korean market

Eli Lilly & Co. has taken its topical testosterone replacement therapy Axiron off the market in Korea after gaining the blessing of the country’s Ministry of Food and Drug Safety. The company said that it made the decision to withdraw the treatment from the market in Korea due to several factors including “low male menopause awareness and the existence of substitutable medicines.” Axiron was developed by Australian pharmaceutical company Acrux and marketed by U.S.-based Lilly. It was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of hypogonadism, a condition in which men do not ... Read More

Third AndroGel side effects trial begins this week

AbbVie Inc. faces its third bellwether trial this week over claims that testosterone replacement therapy AndroGel caused serious cardiovascular injuries. The case is one of more than 7,500 pending in a multidistrict litigation in Illinois federal court that names several testosterone treatment manufacturers and various testosterone products. The latest trial involves the case of Robert Nolte and his wife Genienne, who sued AbbVie in 2014 after Robert suffered a pulmonary embolism, a life threatening condition caused when blood clots travel to the lungs. He claims AbbVie did not adequately warn that use of AndroGel carried cardiovascular risks, including heart attacks, ... Read More

PA schedules 17 testosterone side effects trials through January 2019

Days after Auxilium Inc., settled a lawsuit over claims its testosterone treatment caused an Alabama man to suffer a stroke, a Philadelphia Court of Common Pleas judge scheduled 17 testosterone side effects trials involving multiple testosterone makers to take place between June and January 2019. The Auxilium trial was scheduled to begin Jan. 8, and was filed in 2014. Philadelphia Court of Common Pleas Judge John M. Younge had planned to schedule seven bellwethers during that timeframe, paving the way for a settlement of the nearly 30 cases pending in the court. But instead of making good on a previous ... Read More

Several testosterone side effects trials scheduled through 2019

Three trials involving testosterone side effects have taken place in 2017 and another 10 or 11 cases are scheduled to be tried through 2019, due to U.S. District Judge Matthew Kennelly’s interest in ensuring all plaintiffs and defendants have the benefit of timely bellwethers. The multidistrict litigation is consolidated in the U.S. District Court for the Northern District of Illinois and names a handful of testosterone manufacturers including AbbVie Inc., Eli Lilly & Co., and Auxilium Pharmaceuticals Inc. There are also state cases by Illinois residents against AbbVie. The Cook County judge is coordinating with Judge Kennelly on those cases. ... Read More

Endo faces more testosterone side effects trials

Endo Pharmaceutical may have gotten a pass on the latest testosterone side effects trial, but its problems are far from resolved. The drug company faces nearly 1,300 lawsuits involving its testosterone replacement therapy Testim, as well as other testosterone products it markets, in state and federal courts. Endo faced the third trial in a class action lawsuit against several manufacturers of testosterone treatments over claims that the drugs caused cardiovascular side effects including heart attacks, strokes, blood clots and death. The first two trials were waged against AbbVie Inc., maker of the blockbuster testosterone treatment AndroGel, and resulted in verdicts ... Read More

Auxilium to take hot seat in latest testosterone side effects trial

Weeks after two juries handed down multi-million verdicts to two men who claimed that AbbVie Inc., did not adequately warn of cardiovascular risks with its testosterone replacement therapy AndroGel, drug maker Auxilium Pharmaceuticals LLC will take the hot seat in court over allegations that its testosterone treatment Testim caused a man to suffer a heart attack. Steve Holtsclaw is one of thousands of men alleging manufacturers of testosterone replacement therapy misrepresented what their products were safe and effective to treat while failing to warn that the drugs increased the risk of heart attacks, strokes and blood clots. Holtsclaw claimed he ... Read More

AndroGel makers failed to warn about risks

AbbVie Inc.’s did not properly test its testosterone replacement therapy AndroGel for cardiovascular risks and failed to warn doctors and patients of those risks, an Illinois federal jury found before ordering the company to pay a whopping $140 million dollars in punitive damages plus an additional $140,000 in compensatory damages to a Memphis, Tennessee man. Jeffrey Konrad, who is in his 50s, was prescribed AndroGel in 2010 to treat symptoms of so-called Low T, including low libido, muscle loss and weight gain. But two months after starting treatment he suffered a heart attack. He sued AbbVie in 2014. His lawsuit alleged ... Read More